CD274 and non-small cell lung carcinoma: A previous real-world patient experience in advanced NSCLC demonstrated a significantly improved median and landmark 3-year OS with ICI-based treatment compared to chemotherapy alone in patients with positive plasma cfRNA PD-L1 expression [19].